Literature DB >> 7965776

Interactions between leukotrienes and histamine in the anaphylactic contraction of guinea pig lung parenchyma.

E W Jonsson1, S E Dahlén.   

Abstract

The aim of the study was to investigate if antigen-induced contraction of guinea pig lung parenchyma (GPLP) was an appropriate model for the study of antileukotriene drugs. Antileukotrienes have recently shown antiasthmatic effects in humans. Challenge of GPLP with a cumulatively increasing concentration of antigen evoked a graded contractile response. The antigen response could be divided into an immediate peak phase and a plateau phase of long duration. Histamine antagonism alone (mepyramine, H1, and metiamide, H2) had no effect on the response, whereas 5-lipoxygenase (5-lox) inhibitors (BAY x1005, MK-886 or BWA4C) depressed the plateau phase. When 5-lipoxygenase inhibition (BAY x1005 or MK-886) or cysteinyl-leukotriene receptor antagonism (ICI 198,615) was combined with histamine antagonism, there was a major attenuation of both components of the antigen response, leaving only a small residual response. In contrast, cyclooxygenase inhibition (diclofenac or indomethacin), antagonism of platelet-activating factor (WEB 2086) and thromboxane receptor antagonism combined with inhibition of thromboxane synthesis (BAY u3405 and CS-518) failed to inhibit the antigen response. In conclusion, cysteinyl-leukotrienes and histamine synergistically mediated the major part of the Schultz-Dale response in GPLP. The characteristics of GPLP anaphylaxis closely resembled those of antigen-challenged human bronci, supporting that antigen challenge of GPLP is a suitable model in experimental asthma research.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7965776

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005.

Authors:  B Dahlén; M Kumlin; E Ihre; O Zetterström; S E Dahlén
Journal:  Thorax       Date:  1997-04       Impact factor: 9.139

2.  A new class of nitric oxide-releasing derivatives of cetirizine; pharmacological profile in vascular and airway smooth muscle preparations.

Authors:  A-K Larsson; F Fumagalli; A DiGennaro; M Andersson; J Lundberg; C Edenius; M Govoni; A Monopoli; A Sala; S-E Dahlén; G C Folco
Journal:  Br J Pharmacol       Date:  2007-03-12       Impact factor: 8.739

3.  Specific mediator inhibition by the NO donors SNP and NCX 2057 in the peripheral lung: implications for allergen-induced bronchoconstriction.

Authors:  Anna-Karin Larsson; Magnus Bäck; Jon O Lundberg; Sven-Erik Dahlén
Journal:  Respir Res       Date:  2009-06-04

4.  Short-Term Regulation of FcγR-Mediated Phagocytosis by TLRs in Macrophages: Participation of 5-Lipoxygenase Products.

Authors:  Carla da S Pinheiro; Ana Paula T Monteiro; Fabiano F Dutra; Marcelo T Bozza; Marc Peters-Golden; Claudia F Benjamim; Claudio Canetti
Journal:  Mediators Inflamm       Date:  2017-08-15       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.